NASDAQ:FULC
Fulcrum Therapeutics, Inc. Stock News
$7.75
+0.1000 (+1.31%)
At Close: May 03, 2024
Silverarc Capital Management, Llc Buys Fulcrum Therapeutics Inc, Cogent Biosciences Inc, Cerus ...
03:38pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: COGT , CERS , NXTC , IMTX , CLDX , MCRB , FULC , ARVN , LPTX , ERAS , CYTK , LHDX , DRNA , RNLX , KDNY , MGNX , VSTM , TCRR , ALDX , CGEM ,
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q3 2021 results - Earnings Call Transcript
02:20pm, Saturday, 06'th Nov 2021
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q3 2021 results - Earnings Call Transcript
Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Tops Revenue Estimates
09:57am, Thursday, 04'th Nov 2021
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.94% and 68.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th
Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
07:00am, Wednesday, 03'rd Nov 2021
CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 01'st Oct 2021
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically de
Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society
07:00am, Monday, 20'th Sep 2021
– Presentations highlight progress in the development of losmapimod for FSHD –
Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 10'th Sep 2021
CAMBRIDGE, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
01:24am, Friday, 03'rd Sep 2021
Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
2 Soaring Biotech Stocks With More Fuel in the Tank
06:47am, Monday, 23'rd Aug 2021
These recent winners still have a long way to run.
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock
10:09pm, Wednesday, 11'th Aug 2021
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically de
Why Fulcrum Therapeutics Popped Again on Tuesday
04:06pm, Wednesday, 11'th Aug 2021
Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.
Why Are Fulcrum Therapeutics Shares Trading Higher Today?
09:55am, Wednesday, 11'th Aug 2021
Fulcrum Therapeutics Inc (NASDAQ:FULC) is trading higher again Wednesday after the stock saw positive analyst coverage following the company's better-than-expected financial results and announcement
FULC Stock Price Increased 125.33%: Why It Happened
07:48am, Wednesday, 11'th Aug 2021
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) increased 125.33%. This is why it happened.
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
04:24pm, Tuesday, 10'th Aug 2021
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
